The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25–35)-induced cognitive deficits in mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,417
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 3×
“The dose of 30 mg/kg, corresponding to the equivalent of 4–6 cups of coffee in humans, causes the maximal behavior effects in rodents (Fredholm et al., 1999), whereas the dose of 80 mg/kg is still below toxic dosage and is associated with higher antagonism of adenosine A2A receptors (Quarta et al.”
BackgroundInfluentialHughes, R. N. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.06.006 · Cited by 641
Ciruela, F., Casadó, V., Rodrigues, R. J., Luján, R., Burgueño, J., Canals, M., Borycz, J., Rebola, N., Goldberg, S. R., Mallol, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3574-05.2006 · Cited by 590
Self-citationNeuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
Cunha, R. A. (2005) · Purinergic Signalling · doi:10.1007/s11302-005-0649-1 · Cited by 537
Self-citationMaurice, T., Lockhart, B. P., & Privat, A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01032-7 · Cited by 521
Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease
Klein, W. L., Stine, W. B., & Teplow, D. B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.010 · Cited by 483
Does caffeine intake protect from Alzheimer's disease?
Maia, L., & De Mendonça, A. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00421.x · Cited by 357
Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens
Solinas, M., Ferré, S., You, Z.-B., Karcz-Kubicha, M., Popoli, P., & Goldberg, S. R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06321.2002 · Cited by 338 · cited 4×
“, 1999), of caffeine applied acutely favor A2A receptor antagonism (Karcz-Kubicha et al., 2003; Quarta et al., 2004; Solinas et al., 2002), these results suggest a preferential”
BackgroundInfluentialA focus on the synapse for neuroprotection in Alzheimer disease and other dementias
Coleman, P., Federoff, H., & Kurlan, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140626.48118.0a · Cited by 314
Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity
Dall'lgna, O. P., Porciúncula, L. O., Souza, D. O., Cunha, R. A., & Lara, D. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705185 · Cited by 254
Self-citationPrediger, R. D. S., Batista, L. C., & Takahashi, R. N. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.012 · Cited by 243
Rebola, N., Canas, P. M., Oliveira, C. R., & Cunha, R. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.01.014 · Cited by 202
Self-citationKarcz-Kubicha, M., Antoniou, K., Terasmaa, A., Quarta, D., Solinas, M., Justinova, Z., Pezzola, A., Reggio, R., Müller, C. E., Fuxe, K., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300167 · Cited by 189
Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia
Saura, J., Angulo-Pueyo, E., Ejarque-Ortiz, A., Casadó, V., Tusell, J. M., Moratalla, R., Chen, J., Schwarzschild, M. A., Lluís, C., Franco, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03395.x · Cited by 188
Angulo, E., Casadó, V., Mallol, J., Canela, E. I., Viñals, F., Ferrer, I., Lluis, C., & Franco, R. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00475.x · Cited by 178
Coffee Consumption and Cognitive Function among Older Adults
Johnson-Kozlow, M. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf119 · Cited by 173 · cited 1×
“Furthermore, both caffeine (e.g. Angelucci et al., 1999; Johnson-Kozlow et al., 2002) and selective A2A receptor antagonists (Kopf et al.”
BackgroundSvenningsson, P., Nomikos, G. G., Ongini, E., & Fredholm, B. B. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00046-8 · Cited by 170
Quarta, D., Ferré, S., Solinas, M., You, Z., Hockemeyer, J., Popoli, P., & Goldberg, S. R. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02245.x · Cited by 163
Rebola, N., Sebastião, A. M., de Mendonça, A., Oliveira, C. R., Ribeiro, J. A., & Cunha, R. A. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00896.2002 · Cited by 122
Self-citationThe effect of caffeine in animal models of learning and memory
Angelucci, M. E. M., Vital, M. A. B. F., Cesário, C., Zadusky, C. R., Rosalen, P. L., & Cunha, C. D. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00225-3 · Cited by 109
Xu, K., Xu, Y., Chen, J., & Schwarzschild, M. A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00069-1 · Cited by 105
Harkany, T., Hortobágyi, T., Sasvári, M., Kónya, C., Penke, B., Luiten, P. G. M., & Nyakas, C. J. (1999) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(99)00058-5 · Cited by 105
Kopf, S. R., Melani, A., Pedata, F., & Pepeu, G. (1999) · Psychopharmacology · doi:10.1007/s002130051109 · Cited by 98
Behavioral and cognitive profile of mice with high and low exploratory phenotypes
Kazlauckas, V., Schuh, J. F., Dall'Igna, O. P. P., Pereira, G. S., Bonan, C. D., & Lara, D. R. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.03.021 · Cited by 91
Self-citationde Oliveira, R. V., Dall'Igna, O. P. P., Tort, A. B. L., Schuh, J. F., Neto, P. F., Gomes, M. W. S., Souza, D. O., & Lara, D. R. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200503000-00002 · Cited by 36
Self-citationDall'Igna, O. P. P., Hoffmann, A., da Silva, A. L., Souza, D. O., & Lara, D. R. (2004) · Neurodegenerative Diseases · doi:10.1159/000076668 · Cited by 9
Self-citation
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“Likewise, chronic treatment with caffeine has been shown to be effective in preventing β-amyloid (Aβ) production and memory deficits in experimental models of Alzheimer’s disease [5, 6].”
BackgroundRibeiro, J. A., & Sebastião, A. M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1379 · Cited by 577
Metadata
- Authors
- Dall'Igna, O. P., Fett, P., Gomes, M. W., Souza, D. O., Cunha, R. A., & Lara, D. R.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 203
- Issue
- 1
- Pages
- 241-245
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2163629140
- Cited by
- 372
- References
- 28
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.